Deficit schizophrenia: An update

World Psychiatry

Volumn 7, Issue 3, 2008, Pages 143-147

  Kirkpatrick, Brian ^a   Galderisi, Silvana ^b  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Apathy; Deficit schizophrenia; Double dissociation; Heterogeneity; Negative symptoms

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); AMISULPRIDE; CATECHOL METHYLTRANSFERASE; CLOZAPINE; COLLAPSIN RESPONSE MEDIATOR PROTEIN 2; CYCLOSERINE; DEXTRO SERINE; GLYCINE; METHIONINE; OLANZAPINE; PLACEBO; VALINE;

AMINO ACID SUBSTITUTION; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CORRELATION ANALYSIS; CYTOMEGALOVIRUS; DISEASE COURSE; DRUG EFFICACY; EVENT RELATED POTENTIAL; EVIDENCE BASED MEDICINE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HUMAN; MEDICAL DECISION MAKING; MEDICAL LITERATURE; MEDICAL RESEARCH; NERVOUS SYSTEM ELECTROPHYSIOLOGY; NEUROIMAGING; NEUROPSYCHOLOGY; PATHOPHYSIOLOGY; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR; SCHIZOPHRENIA; SEASONAL VARIATION; SYMPTOM; TREATMENT OUTCOME;

EID: 57049101401     PISSN: 17238617     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.2051-5545.2008.tb00181.x     Document Type: Article

References (59)

1. Carpenter WT Jr, Heinrichs DW, Wagman AMI. Deficit and non-deficit forms of schizophrenia: the concept. Am J Psychiatry 1988; 145:578-83.
2. Kirkpatrick B, Buchanan RW, McKenney PD et al. The Schedule for the Deficit Syndrome: an instrument for research in schizophrenia. Psychiatry Res 1989;30:119-24.
3. Kirkpatrick B, Buchanan RW, Ross DE et al. A separate disease within the syndrome of schizophrenia. Arch Gen Psychiatry 2001; 58:165-71.
4. Carpenter WT. Deconstructing and reconstructing illness syndromes associated with psychosis. World Psychiatry 2007;6:92-3.
5. Hong LE, Avila MT, Adami H et al. Components of the smooth pursuit function in deficit and non-deficit schizophrenia. Schizophr Res 2003;63:39-48.
6. Hong LE, Wonodi I, Avila MT et al. Dihydropyrimidinase-related protein 2 (DRP-2) gene and association to deficit and nondeficit schizophrenia. Am J Med Genet B Neuropsychiatr Genet 2005;136: 8-11.
7. Galderisi S, Maj M, Kirkpatrick B et al. Catechol-O-methyltransferase Val158Met polymorphism in schizophrenia: associations with cognitive and motor impairment. Neuropsychobiology 2005; 52:83-9.
8. Wonodi I, Mitchell BD, Stine OC et al. Lack of association between COMT gene and deficit/nondeficit schizophrenia. Behav Brain Fund 2006;2:42-6.
9. Davies G, Welham J, Chant D et al. A systematic review and meta-analysis of Northern Hemisphere season of birth studies in schizophrenia. Schizophr Bull 2003;29:587-93.
10. Messias E, Kirkpatrick B, Bromet E et al. Summer birth and deficit schizophrenia: a pooled analysis from six countries. Arch Gen Psychiatry 2004;61:985-9.
11. Dickerson F, Kirkpatrick B, Boronow J, et al. Deficit schizophrenia: association with serum antibodies to cytomegalovirus. Schizophr Bull 2006;32:396-400.
12. Goff DC, Bottiglieri T, Arning E et al. Folate, homocysteine, and negative symptoms in schizophrenia. Am J Psychiatry 2004;161: 1705-8.
13. Roffman JL, Weiss AP, Purcell S et al. Contribution of methylenetetrahydrofolate reductase (MTHFR) polymorphisms to negative symptoms in schizophrenia. Biol Psychiatry 2008;63:42-8.
14. Roy MA, Maziade M, Labbé A et al. Male gender is associated with deficit schizophrenia: a meta-analysis. Schizophr Res 2001;47:141-7.
15. Galderisi S, Maj M, Mucci A et al. Historical, psychopathological, neurological and neuropsychological aspects of deficit schizophrenia: a multicenter study. Am J Psychiatry 2002;159:983-90.
16. Tek C, Kirkpatrick B, Buchanan RW. A five-year follow-up study of deficit and non-deficit schizophrenia. Schizophr Res 2001;49:253-60.
17. Chemerinski E, Reichenberg A, Kirkpatrick B et al. Three dimensions of clinical symptoms in elderly patients with schizophrenia: prediction of six-year cognitive and functional status. Schizophr Res 2006;85:12-9.
18. Murphy BP, Chung Y-C, Park T-W et al. Pharmacological treatment of primary negative symptoms in schizophrenia: a systematic review. Schizophr Res 2006;88:5-25.
19. Leucht S, Pitschel-Walz G, Engel RR et al. Amisulpride, an unusual "atypical" antipsychotic: a meta-analysis of randomized controlled trials. Am J Psychiatry 2002;159:180-90.
20. Buchanan RW, Breier A, Kirkpatrick B et al. Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome. Am J Psychiatry 1998;55:751-60.
21. Kopelowicz A, Zarate R, Tripodis K et al. Differential efficacy of olanzapine for deficit and non-deficit negative symptoms in schizophrenia. Am J Psychiatry 2000;157:987-93.
22. Lindenmayer J-P, Khan A, Iskander A et al. A randomized controlled trial of olanzapine versus haloperidol in the treatment of primary negative symptoms and neurocognitive deficits in schizophrenia. J Clin Psychiatry 2007;68:368-79.
23. Evins AE, Amico E, Posever TA et al. D-cycloserine added to risperidone in patients with primary negative symptoms of schizophrenia. Schizophr Res 2002;56:19-23.
24. Goff DC, Tsai G, Levitt J et al. A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. Arch Gen Psychiatry 1999;56:21-7.
25. Tsai G, Yang P, Chung LC et al. D-serine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 1998; 44:1081-9.
26. Tsai GE, Yang P, Chung LC et al. D-serine added to clozapine for the treatment of schizophrenia. Am J Psychiatry 1999;156:1822-5.
27. Buchanan RW, Javitt DC, Marder SR et al. The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. Am J Psychiatry 2007;164:1593-602.
28. Javitt DC. Is the glycine site half saturated or half unsaturated? Effects of glutamatergic drugs in schizophrenia patients. Curr Opin Psychiatry 2006;19:151-7.
29. Buchanan RW, Strauss ME, Kirkpatrick B et al. Neuropsychological impairments in deficit vs nondeficit forms of schizophrenia. Arch Gen Psychiatry 1994;51:804-11.
30. Putnam KM, Harvey PD. Cognitive impairment and enduring negative symptoms: a comparative study of geriatric and nongeriatric schizophrenia patients. Schizophr Bull 2000;26:867-78.
31. Bryson G, Whelahan HA, Bell M. Memory and executive function impairments in deficit syndrome schizophrenia. Psychiatry Res 2001;102:29-37.
32. Wang X, Yao S, Kirkpatrick B et al. Psychopathology and neuropsychological impairments in deficit and nondeficit schizophrenia of Chinese origin. Psychiatry Res (in press).
33. Brazo P, Marié RM, Halbecq I et al. Cognitive patterns in subtypes of schizophrenia. Eur Psychiatry 2002;17:155-62.
34. Tiryaki M, Yazici KA. Anil AE et al. Reexamination of the characteristics of the deficit schizophrenia patients. Eur Arch Psychiatry Clin Neurosci 2003; 253:221-7.
35. Seckinger RA, Goudsmit N, Coleman E et al. Olfactory identification and WAIS-R performance in deficit and nondeficit schizophrenia. Schizophr Res 2004;69:55-65.
36. Cascella NG, Testa SM, Meyer SM et al. Neuropsychological impairment in deficit vs. non-deficit schizophrenia. J Psychiatr Res (in press).
37. Cohen AS, Saperstein AM, Gold JM et al. Neuropsychology of the deficit syndrome: new data and meta-analysis of findings to date. Schizophr Bull 2007;33:1201-12.
38. Polgár P, Farkas M, Nagy O et al. How to find the way out from four rooms? The learning of "chaining" associations may shed light on the neuropsychology of the deficit syndrome of schizophrenia. Schizophr Res 2008;99:200-7.
39. Keefe RSE. Should cognitive impairment be included in the diagnostic criteria for schizophrenia? World Psychiatry 2008;7:22-8.
40. Arango C, Kirkpatrick B, Buchanan RW. Neurological signs and the heterogeneity of schizophrenia. Am J Psychiatry 2000;157:560-5.
41. Cimmer C, Szendi I, Csifcsák G et al. Abnormal neurological signs, visual contrast sensitivity, and the deficit syndrome of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2006;30:1225-30.
42. Gur RE, Mozley PD, Shtasel DL et al. Clinical subtypes of schizophrenia: differences in brain and CSF volume. Am J Psychiatry 1994;151:343-50.
43. Sigmundsson T, Suckling J, Maier M et al. Structural abnormalities in frontal, temporal, and limbic regions and interconnecting white matter tracts in schizophrenic patients with prominent negative symptoms. Am J Psychiatry 2001;158:234-43.
44. Quarantelli M, Larobina M, Volpe U et al. Stereotaxy-based regional brain volumetry applied to segmented MRI: validation and results in deficit and non-deficit schizophrenia. Neuroimage 2002; 17:373-84.
45. Galderisi S, Quarantelli M, Volpe U et al. Patterns of structural MRI abnormalities in deficit and non-deficit schizophrenia. Schizophr Bull 2008;34:393-401.
46. Tamminga CA, Thaker GK, Buchanan RW et al. Limbic system abnormalities identified in schizophrenia using positron emission tomography with fluorodeoxyglucose and neocortical alterations with deficit syndrome. Arch Gen Psychiatry 1992;49:522-30.
47. Ross DE, Thaker GK, Holcomb HH et al. Abnormal smooth pursuit eye movements in schizophrenic patients are associated with cerebral glucose metabolism in oculomotor regions. Psychiatry Res 1995;58:53-67.
48. Carpenter WT, Lahti AC, Holcomb HH et al. Frontal and parietal blood flow activation during an auditory task differentiate schizophrenic patients with and without primary negative symptoms. Abst Soc Neurosci 1996;22:676.
49. Heckers S, Goff D, Schacter DL et al. Functional imaging of memory retrieval in deficit vs non-deficit schizophrenia. Arch Gen Psychiatry 1999;56:1117-23.
50. Lahti AC, Holcomb HH, Medoff DR et al. Abnormal patterns of regional cerebral blood flow in schizophrenia with primary negative symptoms during an effortful auditory recognition task. Am J Psychiatry 2001;158:1797-808.
51. Vaiva G, Cottencin O, Llorca PM et al. Regional cerebral blood flow in deficit/non-deficit types of schizophrenia according to SDS criteria. Prog Neuropsychopharmacol Biol Psychiatry 2002;26:481-5.
52. Gonul AS, Kula M, Esel E et al. A Tc-99m HMPAO SPECT study of regional cerebral blood flow in drug-free schizophrenic patients with deficit and non-deficit syndrome. Psychiatry Res: Neuroimaging 2003;123:199-205.
53. Delamillieure P, Fernandez J, Constans JM et al. Proton magnetic resonance spectroscopy of the medial prefrontal cortex in patients with deficit schizophrenia: preliminary report. Am J Psychiatry 2000; 157:641-3.
54. Turetsky BI, Colbath EA, Gur RE. P300 subcomponent abnormalities in schizophrenia: I. Physiological evidence for gender and sub-type specific differences in regional pathology. Biol Psychiatry 1998; 43:84-96.
55. Bucci P, Mucci A, Merlotti E et al. Induced gamma activity and event-related coherence in schizophrenia. Clin EEG Neurosci 2007; 38:97-104.
56. Mucci A, Galderisi S, Kirkpatrick B et al. Double dissociation of N1 and P3 abnormalities in deficit and nondeficit schizophrenia. Schizophr Res 2007;92:252-61.
57. Kimhy D, Yale S, Goetz RR et al. The factorial structure of the Schedule for the Deficit Syndrome in Schizophrenia. Schizophr Bull 2006;32:274-8.
58. Blanchard JJ, Cohen AS. The structure of negative symptoms within schizophrenia: implications for assessment. Schizophr Bull 2006;32:238-45.
59. Kirkpatrick B, Kopelowicz A, Buchanan RW et al. Assessing the efficacy of treatments for the deficit syndrome of schizophrenia. Neuropsychopharmacology 2000;22:303-10.